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httpDevelopment of a duplex-derived velocity risk
prediction model of disease progression in patients
with moderate asymptomatic carotid artery stenosis
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Natalia O. Glebova, MD, PhD, Eric Schneider, PhD, Umair Qazi, MD, MPH, Bruce Perler, MD,
and Mahmoud B. Malas, MD, MHS, Baltimore, Md
Objective: Previously, we described risk factors for disease progression in moderate asymptomatic carotid artery stenosis
(ASCAS). The aim of the current study was to develop a risk prediction model for disease progression in this group.
Methods: All patients presenting between January 2005 and May 2012 with moderate (50%-69%) ASCAS, as determined
by carotid artery duplex imaging, were included. Cox proportional hazard regression models accounting for measured
duplex peak systolic velocity and end-diastolic velocity, and the internal carotid artery (ICA)/common carotid artery
(CCA) ratio, with and without previously identiﬁed risk factors for progression (age, smoking, dual antiplatelet therapy),
were used to develop receiver operating characteristic curves for predicting disease progression.
Results: The study analyzed 282 patients (52% male), aged 71 6 9 years, with 2.6 6 0.1 years follow-up and 25% disease
progression at a mean time of 2.02 6 0.18 years. Initial peak systolic velocity, end-diastolic velocity, and the ICA/CCA
ratio were all signiﬁcant independent predictors of progression. Receiver operating characteristic curve analyses suggested
that a prediction model based on ICA/CCA ratio alone had optimal prediction efﬁcacy (hazard ratio, 2.01; Harrell’s
C, 0.74; P < .001). Patients with ICA/CCA >2.5, 3.3, and 3.8 were found to have >10%, >20%, and >30% risk of disease
progression over 2 years, respectively. Model sensitivity and speciﬁcity for predicting 10% risk of disease progression at
2 years was 80.7% and 64.0%, respectively (positive predictive value, 22.9%; negative predictive value, 96.1%).
Conclusions: We propose a clinical prediction model for moderate ASCAS disease progression that can be used to risk-
stratify patients with >10% risk of progression at 2 years using ICA/CCA ratios. Implementation of this model may
be useful for identifying high-risk patients who would beneﬁt from routine carotid disease surveillance follow-up. (J Vasc
Surg 2014;60:1585-92.)Stroke is associated with a 5-year mortality of 50% to
60% and is the leading cause of disability within the United
States and Western Europe.1 Carotid artery stenosis is
thought to account for 10% to 20% of all strokes and can
be found in up to 10% of patients, particularly among older
patients.2,3 The degree of carotid artery stenosis has been
found to be the strongest single determinant of stroke
risk, with a 60% to 70% reduction in carotid artery luminal
diameter associated with a signiﬁcant increase in risk.4
Based on level 1 evidence,5 the European Carotid Sur-
gery Trial,6-11 the Society for Vascular Surgery (SVS),12
and American Heart Association/American Stroke Associa-
tion have put forth guidelines supporting the use of carotidthe Division of Vascular and Endovascular Therapy, Johns Hopkins
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://dx.doi.org/10.1016/j.jvs.2014.08.056endarterectomy in symptomatic patients with >50% carotid
stenosis who have an estimated perioperative morbidity and
mortality risk of <6%, or asymptomatic patients with$60%
stenosis and an estimated perioperative morbidity and mor-
tality risk of <3%.13,14
However, there are no current guidelines regarding the
treatment of patients with an asymptomatic carotid artery ste-
nosis (ASCAS) measuring 50% to 69%. Furthermore, there is
no consensus about howoften patients who are found to have
moderate (50%-69%) ASCAS should be restudied after the
initial diagnosis.12 Some data from >15 years ago suggest
that carotid artery duplex measurements (speciﬁcally, the
peak systolic velocity [PSV]) can help predict disease progres-
sion among patients with <60% ASCAS.15,16 However,
changes in carotid artery plaque composition and advances
in medical management and secondary prevention strategies
since that time may have altered previously identiﬁed predic-
tive parameters for disease progression.17
In an effort to address this practice gap, we previously
described the rate and clinical risk factors for disease pro-
gression among a modern group of patients with moderate
ASCAS.18 We demonstrated that although most patients
with moderate ASCAS remained asymptomatic, more
than one-quarter of patients would progress to severe dis-
ease. Smoking and dual-antiplatelet therapy were inde-
pendent risk factors for disease progression. The aim of
the current study was to develop a risk prediction model
for disease progression using carotid artery duplex1585
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tices in this group.METHODS
The hospital’s Institutional Review Board approved the
study. Informed consent was waived because this was a
retrospective review.
Study design. We retrospectively reviewed all patients
undergoing initial carotid artery duplex between January
2005 and May 2012. Only patients who were asymptomatic
at the time of screening and had moderate (50%-69%)
carotid artery stenosis on initial carotid artery duplex imag-
ing were included. The study excluded patients with symp-
toms at the initial visit, those with severe or symptomatic
contralateral disease, those who underwent carotid revascu-
larization with carotid endarterectomy or stent #30 days of
diagnosis, those with missing carotid duplex measurements
at their initial or follow-up study, and those without a
repeat carotid duplex follow-up study at least 1 year after
their initial study.
The electronic medical records for all included patients
were reviewed for information pertaining to patient demo-
graphics, comorbidities, smoking status, history of periph-
eral arterial disease and contralateral carotid artery
stenosis, and medication use, including aspirin, anticoagu-
lants, statins, angiotensin-converting enzyme inhibitors,
b-blockers, and insulin. PSV, end-diastolic velocity
(EDV), and internal carotid artery/common carotid artery
(ICA/CCA) ratio measurements from the initial and all
subsequent carotid artery duplex studies were recorded.
The primary outcome of the study was the progression of
moderate (50%-69%) carotid artery stenosis to severe
($70%) stenosis, as noted on the patient’s most recent ca-
rotid artery duplex ﬁndings.
Moderate carotid artery stenosis was deﬁned as a
PSV >125 cm/s and <230 cm/s, EDV >40 cm/s
and <100 cm/s, and ICA/CCA ratio >2.0 and <4.0 on
the carotid artery duplex examination as performed by a regis-
tered vascular technologist. All studies were performed in our
vascular diagnostic laboratories, which are accredited by the
Intersocietal Commission for the Accreditation of Vascular
Laboratories.
Statistical methods. Patient demographics and other
baseline characteristics are described using mean6 standard
error of the mean or as counts (%), as appropriate. Standard
univariable analyses using Student t-tests for continuous var-
iables or Pearson c2 tests for categoric variables were used to
compare baseline characteristics and initial carotid artery
duplex measurements (PSV, EDV, ICA/CCA ratio) be-
tween patients withmoderate ASCAS progression and those
without progression.
Multivariable analyses using abbreviated and extended
Cox proportional hazard regression models were performed
to assess the association between PSV, EDV, and the ICA/
CCA ratio with disease progression. Only the most recent
duplex examination for each patient was analyzed. Cox pro-
portional hazards modeling was chosen to account fordifferences in time between the initial and last follow-up
duplex between patients.
Covariates in the extended models were chosen a priori
and included age, dual-antiplatelet therapy, smoking,
female gender, hypertension, diabetes, hyperlipidemia,
coronary artery disease (CAD), kidney disease, statin use,
and aspirin use in accordance with the variables used in
our initial study.18 Covariates in the abbreviated models
included age, smoking status, and dual-antiplatelet therapy
use because results from our previous study demonstrated
that smoking and dual-antiplatelet therapy use were inde-
pendent predictors of moderate ASCAS progression.18
Smoking was deﬁned for the abbreviated and extended
models as “ever-smokers” based on ﬁndings from our prior
study that there were no signiﬁcant differences in disease
progression between prior smoking and current smoking.18
Receiver operating characteristic (ROC) curve analyses
of each unadjusted and adjusted Cox proportional hazards
model were performed to determine the predictive ability of
PSV, EDV, and ICA/CCA alone and in combination based
on Harrell’s C statistics.19 Harrell’s C statistic is analogous
to a C statistic (area under an ROC curve) when analyzing
longitudinal survival data instead of cross-sectional event
data. ROC curve analyses were used to determine the cutoff
at which a measure was able to most accurately predict
a $10% risk of disease progression to severe stenosis at
2 years. The 10% risk probability was chosen based on
perceived clinical effect and the previously reported observa-
tion that disease progression in patients with ASCAS fol-
lowed a linear trend, including 7.6% progression at 1 year,
17.6% progression at 2 years, and 25.1% progression over-
all.18 The 2-year period was chosen based on mean time
to disease progression within the study cohort and the
observation of a signiﬁcant degradation in model accuracy
outside of 2 years.
Prediction model reliability was validated using sub-
group analyses and split-sample training. For the latter, a
random training set and test set were generated using
data from within the same study cohort, and Harrell’s C
statistics for the full cohort vs test cohort were compared
to assess reliability of the predictive model.19
Stata 12 software (StataCorp LP, College Station, Tex)
was used for all analyses. All P -values are two-tailed and
considered signiﬁcant at P # .05.
RESULTS
Cohort characteristics. Overall, 282 patients with ca-
rotid duplex imaging velocities were analyzed. The mean
age at the ﬁrst duplex examination was 70.6 6 0.55 years,
147 patients (52.1%) were male, and 246 (87.2%) were
white. The mean follow-up time was 2.6 6 0.10 years.
Disease progression from moderate ASCAS to severe ca-
rotid artery stenosis occurred in 71 patients (25.2%) at a
mean time of 2.02 6 0.18 years.
Baseline comorbidities and demographic characteristics
were similar in patients who experienced carotid artery dis-
ease progression compared with those who did not, with
the exception of dual-antiplatelet therapy use. As previously
Table I. Demographic characteristics of patients with and without progression of moderate asymptomatic carotid artery
stenosis (ASCAS) to severe carotid artery stenosis
Baseline characteristica ASCAS progression (n ¼ 71) No progression (n ¼ 211) P value
Age, years 70.3 6 1.2 70.8 6 0.6 .70
Female 43.7 49.03 .44
White race 85.9 87.8 .46
Body mass index, kg/m2 27.6 6 0.90 27.8 6 0.40 .82
Smoking 76.1 71.9 .11
Curret smokers 19.7 14.1 .22
Former smokers 62.1 57.8 .38
Hypertension 86.0 84.0 .70
Diabetes mellitus
Noninsulin dependent 16.9 22.3 .33
Insulin dependent 8.45 11.2 .52
Hyperlipidemia 80.3 76.2 .48
CAD 47.9 48.5 .92
Congestive heart failure 7.04 6.3 .83
COPD 11.3 8.25 .44
Abdominal aortic aneurysm 7.04 6.31 .83
Chronic kidney disease 8.45 13.1 .30
Statin 81.7 82.0 .95
Aspirin 87.3 87.9 .91
Anticoagulant 11.3 15.1 .43
Dual antiplatelet therapy 40.9 27.7 .04
ACE inhibitor 35.2 42.2 .30
b-blocker 63.4 60.7 .69
Calcium channel blocker 32.4 33.5 .87
Prior contralateral carotid intervention 4.22 4.74 .83
ACE, Angiotensin converting enzyme; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease.
aContinuous data are presented as mean 6 standard error of the mean and categoric data as percentage.
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ing dual-antiplatelet therapy compared with those without
progression (40.9% vs 27.7%; P ¼ .04; Table I). Baseline
carotid duplex measurements, including PSV, EDV, and
the ICA/CCA ratio, were all signiﬁcantly higher in patients
with progression compared with those with stable disease
(Table II).
Association between initial carotid duplex mea-
surements and disease progression. We previously
demonstrated that the adjusted risk of ASCAS progression
in this patient cohort was higher in patients receiving dual-
antiplatelet therapy (hazard ratio [HR], 1.87; 95%
conﬁdence interval [CI], 1.10-3.16; P ¼ .02) and in ever-
smokers (HR, 1.91; 95% CI, 0.99-3.64; P ¼ .05). Age,
female gender, hypertension, diabetes, hyperlipidemia,
CAD, kidney disease, statin use, and aspirin use were not
signiﬁcant predictors of progression frommoderate to severe
stenosis.18
In the present study, we evaluated the association be-
tween carotid duplex measurements and disease progres-
sion. Univariable analysis showed that initial PSV, EDV,
and ICA/CCA ratio measurements were all signiﬁcantly
associated with signiﬁcantly increased HRs of disease pro-
gression (P < .0001; Table III). Multivariable Cox regres-
sion analysis correcting for age, use of dual antiplatelet
therapy, and smoking, found that the initial PSV, EDV,
and the ICA/CCA ratio remained independent predictors
of disease progression (P < .0001; Table III). Results of
multivariable Cox regression correcting for all previously
explored model covariates (age, dual antiplatelet therapy,smoking, female gender, hypertension, diabetes, hyperlip-
idemia, CAD, kidney disease, statin use, and aspirin use)
were consistent with these ﬁndings, with PSV, EDV, and
the ICA/CCA ratio remaining independent predictors of
progression after risk adjustment (P < .0001; data not
shown).
Prediction model derivation. ROC curve analyses of
Cox regression models containing each of the three base-
line carotid duplex measures separately and together are re-
ported in Table III. Each of the unadjusted models was
signiﬁcantly predictive of disease progression (Harrell’s C,
0.69-0.77; all P < .0001). After adjusting for age, dual-
antiplatelet use, and smoking, the models were similarly
predictive of progression (Harrell’s C, 0.72-0.78; all
P < .0001). Harrell’s C was similar comparing the unad-
justed vs adjusted versions for each of the seven prediction
models that we tested (all P ¼ NS; Table III), suggesting
that the addition of age, dual-antiplatelet use, and smoking
as model covariates had no signiﬁcant effect on model
discrimination.
Based on these ﬁndings, we investigated the utility of
the simplest possible model to predict disease progression.
The ICA/CCA ratio was the strongest independent pre-
dictor for disease progression on univariable (HR, 2.01;
P < .0001) and multivariable (HR, 1.90; P < .0001) anal-
ysis (Table III), with an unadjusted Harrell’s C of 0.74
(Fig 1, A). Using ROC curve analyses, we found that the
ICA/CCA ratio optimally predicted ASCAS disease pro-
gression with a probability cutoff of 0.10 (Fig 1, B).
Assuming this $10% risk of progression as a positive test,
Table III. Receiver operator characteristic (ROC) analyses of risk-prediction models for disease progression in moderate
asymptomatic carotid artery stenosis (ASCAS)
Model
No.
Model
covariates
Risk of disease progression Harrell’s C statistic
Unadjusted HR
(95% CI)
Adjusted HRa
(95% CI)
Unadjusted
(95% CI)
Adjusteda
(95% CI)
Adjusted vs unadjusted
P value
1 PSV 1.01b (1.01-1.01) 1.01b (1.01-1.02) 0.74b (0.68-0.81) 0.76b (0.69-0.82) .30
2 EDV 1.02b (1.01-1.03) 1.03b (1.01-1.04) 0.69b (0.61-0.76) 0.72b (0.65-0.78) .23
3 ICA/CCA ratio 2.01b (1.61-2.50) 1.90b (1.52-2.39) 0.74b (0.69-0.80) 0.75b (0.70-0.81) .57
4 PSVþ 1.01b (1.01-1.01) 1.01b (1.00-1.01) 0.74b (0.68-0.81) 0.76b (0.70-0.82) .19
EDV 1.00 (0.99-1.01) 1.01 (1.00-1.02)
5 PSVþ 1.01b (1.00-1.01) 1.01b (1.00-1.01) 0.77b (0.71-0.82) 0.77b (0.71-0.83) .96
ICA/CCA 1.50b (1.15-1.95) 1.38b (1.04-1.84)
6 EDVþ 1.02b (1.01-1.03) 1.02b (1.01-1.03) 0.76b (0.71-0.82) 0.76b (0.71-0.82) .71
ICA/CCA 1.96b (1.56-2.47) 1.81b (1.43-2.30)
7 PSVþ 1.01b (1.00-1.01) 1.01b (1.00-1.01) 0.77b (0.72-0.82) 0.78b (0.72-0.83) .50
EDVþ 1.01 (0.99-1.02) 1.01 (1.00-1.02)
ICA/CCA 1.59b (1.20-2.11) 1.49b (1.11-2.00)
CCA, Common carotid artery; CI, conﬁdence interval; EDV, end-diastolic velocity;HR, hazard ratio; ICA, internal carotid artery; PSV, peak systolic velocity.
aAdjusted for age, smoking, and dual-antiplatelet therapy.
bP < .05.
Table II. Carotid duplex measurements for patients with and without progression of moderate asymptomatic carotid
artery stenosis (ASCAS) to severe carotid artery stenosis
Measure
ASCAS progression (n ¼ 71),
mean 6 SEM
No progression (n ¼ 211),
mean 6 SEM P value
Baseline
PSV, mm Hg 215 6 9 207 6 4 <.0001
EDV, mm Hg 66.6 6 3.1 54.6 6 1.5 <.0001
ICA/CCA ratio 3.06 6 0.10 2.41 6 0.05 <.0001
Follow-up
Change in PSV, mm Hg 52.3 6 10.1 0.41 6 2.24 <.0001
Change in EDV, mm Hg 19.8 6 32.5 1.82 6 10.3 <.0001
Change in ICA/CCA ratio 1.22 6 1.39 0.02 6 0.03 <.0001
CCA, Common carotid artery; EDV, end-diastolic velocity; ICA, internal carotid artery; PSV, peak systolic velocity; SEM, standard error of the mean.
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ASCAS progression with a sensitivity of 80.7% and a spec-
iﬁcity of 64.0%. The positive and negative predictive values
of ICA/CCA >2.5 for predicting progression were 22.9%
and 96.1%, respectively. Overall, a ICA/CCA ratio cutoff
of 2.5 correctly classiﬁed 2-year ASCAS progression in
65.9% of patients. Further analyses identiﬁed ICA/CCA
ratios of >3.3 and >3.8 as the cutoff at which this measure
optimally predicted progression risks of $20% and $ 30%
at 2 years, respectively (Table IV).
Validation of the ICA/CCA ratio as a clinical pre-
diction tool. To assess the reliability of using only the
ICA/CCA ratio to predict ASCAS disease progression,
we performed subgroup analyses to assess model discrimi-
nation within a variety of different patient cohorts. The
ICA/CCA Harrell’s C was similar comparing older
($65 years) vs younger (<65 years) patients, smokers
(ever-smoker, prior smokers, and current smokers) vs non-
smokers, and patients with vs without dual-antiplatelet
therapy (all P ¼ NS; Table V). There were also no signif-
icant differences in the ICA/CCA Harrell’s C comparingsurgical location (main vs ancillary hospital), patient
gender, aspirin use, statin use, or major comorbidities (all
P ¼ NS; Table V).
To validate the use of the ICA/CCA ratio to predict
ASCAS progression, we performed a split-sample training
and test run on a randomly generated portion of our orig-
inal cohort (50% in each group). Within the training sam-
ple, the ICA/CCA ratio was associated with disease
progression with a HR of 2.08 (95% CI, 1.55-2.79). The
results from the model using the training sample were
then applied to the test sample and were able to predict
ASCAS progression to severe stenosis with a Harrell’s C
of 0.72 (95% CI, 0.63-0.80), which was not signiﬁcantly
different from the original Harrell’s C of 0.74 (95% CI,
0.68-0.81) generated using the full derivation cohort.
DISCUSSION
The appropriate management of patients with asymp-
tomatic moderate (50%-69%) carotid artery stenoses is
unclear.11,20 Furthermore, the appropriateness of postdiag-
nosis surveillance for progression of carotid disease among
Fig 1. Use of the internal carotid artery (ICA)/common carotid artery (CCA) ratio for predicting asymptomatic
carotid artery stenosis (ASCAS) progression. A, Receiver operating characteristic (ROC) curve analyses suggested that
the ICA/CCA ratio at initial presentation alone could predict progression of ASCAS to severe carotid artery stenosis
with the simplest maximum efﬁcacy (Harrell’s C, 0.74). B, Assuming a $10% risk of progression as a positive test, a
ICA/CCA ratio cutoff of 2.5 was able to predict 2-year ASCAS progression with a sensitivity of 80.7% and speciﬁcity
of 64.0%.
Table IV. Internal carotid artery (ICA)/common
carotid artery (CCA) ratio efﬁcacy for predicting 2-year
risk of asymptomatic carotid artery stenosis (ASCAS)
progression
Prediction performance
Risk of ASCAS progression at
2 years
$10% $20% $30%
ICA/CCA ratio cutoff value 2.5 3.3 3.8
Sensitivity, % 80.7 41.9 6.45
Speciﬁcity, % 64.0 91.4 97.4
Positive predictive value, % 22.9 39.4 25.0
Negative predictive value, % 96.1 92.2 88.7
Correct classiﬁcations, % 65.9 85.6 86.7
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do not endorse routine surveillance with duplex ultrasound
imaging for progression of moderate (50%-69%) ASCAS on
the assumption that the overall risk of stroke is low in patients
without pre-existing evidence of cerebral ischemia.3,13,14,21
However, our data and other data on this topic22-30 suggest
that patients with identiﬁable risk factors for carotid artery dis-
ease progression may warrant more careful follow-up.
We previously demonstrated that among a cohort of 258
asymptomatic patients with moderate ASCAS, >25% of pa-
tients will have disease progression to severe ($70% stenosis)
by a mean time of 2 years. In the current study, we used the
same patient cohort to evaluate the predictive efﬁcacy of ca-
rotid duplexmeasurements for identifying patients withmod-
erate ASCASwho are at increased risk for disease progression.
Using multivariable modeling and ROC curve analyses, we
found that an ICA/CCA ratio >2.5 on the initial screening
duplex was themost accurate predictor of disease progression
in this group. Furthermore, the predictive efﬁcacy of the
model was largely unchanged with the addition of other clin-
ical factors, making the ICA/CCA ratio a simple, clinically
applicable means by which physicians could potentially iden-
tify high-risk patients.
Based on the ﬁndings of this study, we suggest that
routine surveillance follow-up with carotid duplex imaging
could be targeted to certain patients at high risk for disease
progression based on their initial ICA/CCA ratio, thereby
maximizing screening efﬁcacy to identify and prevent strokes
in high-risk patients with moderate ASCAS in a cost-
effectivemanner.We propose such an algorithm in themod-
erate ASCAS decision-making tree presented in Fig 2.
The precise times at which postdiagnosis surveillance
imaging should be performed are unclear. We previously
reported a 7.6% incidence of moderate ASCAS progres-
sion at 1 year, 17.6% at 2 years, and 35.9% at 4 years.18
On the basis of these observations, combined with the
fact that the carotid progression risk prediction modelwe present here was constructed around a 2-year risk
of progression, we would recommend 1-year surveillance
intervals for patients with an ICA/CCA ratio >2.5. This
approach may be slightly more frequent than needed,
but the risks associated with duplex imaging are low
compared with the potential morbidity and mortality
that is associated with stroke.31
Patients who meet criteria for 20% and 30% risk of pro-
gression (ie, ICA/CCA ratio >3.3 and 3.8, respectively)
would likely beneﬁt from more frequent surveillance (eg,
every 3 or 6 months), although the optimal interval is un-
clear from the available data, and insurer buy-in would be
required to implement this approach. The senior author
(M.B.M.) recently included this enhanced screening in
his practice, and to our knowledge, has not encountered
an issue with insurance coverage to date. It is possible
that patients with other risk factors, such as smoking and
dual-antiplatelet use, would also beneﬁt from more
frequent surveillance, although the data in our cohort did
not demonstrate a clear beneﬁt in predictive efﬁcacy by
adding clinical factors into the model.
Table V. Subgroup analyses of internal carotid artery (ICA)/common carotid artery (CCA) ratio as predictor of disease
progression
Subgroup
HR (95% CI) Harrell’s C (95% CI)
Yes No Yes No
Age <65 years 2.19 (1.25-3.85) 2.00 (1.57-2.54) 0.69 (0.56-0.83) 0.76 (0.70-0.82)
Smoking
Ever 1.85 (1.45-2.35) 3.46 (1.51-7.94) 0.74 (0.67-0.80) 0.77 (0.64-0.90)
Prior 1.77 (1.35-2.31) 0.73 (0.66-0.81)
Current 3.21 (1.38-7.49) 0.74 (0.60-0.87)
Dual-antiplatelet therapy 1.85 (1.38-2.48) 2.03 (1.47-2.79) 0.77 (0.69-0.84) 0.73 (0.65-0.81)
Main hospital 1.98 (1.43-2.74) 1.96 (1.44-2.64) 0.77 (0.69-0.85) 0.72 (0.65-0.80)
Male gender 2.10 (1.43-3.07) 1.94 (1.45-2.58) 0.74 (0.66-0.81) 0.75 (0.68-0.83)
Hypertension 2.01 (1.55-2.60) 2.06 (1.30-3.25) 0.72 (0.66-0.78) 0.84 (0.73-0.95)
Diabetes mellitus
Noninsulin dependent 2.38 (1.05-5.37) 1.99 (1.58-2.51) 0.73 (0.60-0.86) 0.75 (0.69-0.81)
Insulin dependent 3.12 (1.15-8.49) 1.98 (1.57-2.49) 0.81 (0.61-1.01) 0.74 (0.69-0.80)
Hyperlipidemia 2.13 (1.66-2.73) 1.74 (1.06-2.84) 0.76 (0.71-0.82) 0.67 (0.52-0.82)
CAD 1.89 (1.37-2.59) 2.10 (1.56-2.84) 0.74 (0.66-0.82) 0.75 (0.68-0.83)
Chronic kidney disease 1.65 (0.58-4.66) 2.01 (1.61-2.51) 0.77 (0.56-0.98) 0.74 (0.68-0.80)
Statin 1.99 (1.58-2.50) 1.76 (0.70-4.39) 0.75 (0.69-0.81) 0.70 (0.53-0.88)
Aspirin 2.03 (1.62-2.53) 1.42 (0.49-4.14) 0.75 (0.70-0.81) 0.61 (0.43-0.79)
CAD, Coronary artery disease; CI, conﬁdence interval; HR, hazard ratio.
Fig 2. Proposed decision-making tree for the surveillance of moderate (50%-69%) asymptomatic carotid artery stenosis
(ASCAS). CCA, Common carotid artery; ICA, internal carotid artery.
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prediction model suggests a risk of disease progression
of <5% in patients with an ICA/CCA ratio of #2.5. We
would argue that patients who fall below this threshold
can likely be discharged from regular surveillance unless
their clinical picture changes, in accordance with the previ-
ously mentioned American Society of Neuroimaging
guidelines that quote a lack of cost-effectiveness and poten-
tial for harm among patients with an assumed disease prev-
alence of <5%.32
Our ﬁnding that the ICA/CCA ratiowas the best predic-
tor of disease progression is novel. Current consensus criteria
use ICA PSV thresholds of $125 cm/s and $230 cm/s fordiagnosing $50% and $70% carotid artery stenosis, respec-
tively.12 These guidelines are based on recommendations
made by the Society of Radiologists in Ultrasound, who
met in 2002 to publish formal criteria for the diagnosis of ca-
rotid artery stenosis using duplex ultrasound imaging based
on a combination of published data and expert opinion.33
Since that time, AbuRahma et al34 have lauded the accuracy
of PSV over EDV and the ICA/CCA ratio for diagnosing ca-
rotid artery stenosis. Using angiography as the gold standard,
they quote an overall accuracy of 85% using PSV for diag-
nosing carotid artery stenosis $50% vs 81% with the ICA/
CCA ratio. Our study found that PSV, EDV, and the
ICA/CCA ratio were all independent predictors of ASCAS
JOURNAL OF VASCULAR SURGERY
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for progression with an ICA/CCA ratio and a corresponding
Harrell’s C of 0.74, we chose to use this measurement in our
clinical predictionmodel over PSV or EDV,which had similar
Harrell’s C values but notably lower HRs.
Although PSV is a commonly reported measure among
historical reports of ASCAS progression,15,16 the ICA/
CCA ratio is infrequently studied. On the basis of prior
ﬁndings that the ICA/CCA ratio tends to overdiagnose ca-
rotid disease compared with PSV,34 we predict that the
ICA/CCA ratio may have increased sensitivity for subtle
changes in carotid velocities that are lost with other mea-
sures. Although velocities can increase due to several phys-
iologic factors, the ICA/CCA ratio may be a more accurate
predictor of local disease progression.
A model that has a tendency to overpredict disease pro-
gression is preferable to one that underpredicts progression
when it is to be used for screening purposes, because
screening too many patients poses less clinical risk than
screening too few, particularly when stroke is the outcome
one is trying to prevent. Of note, our ﬁnding that an
ICA/CCA ratio >2.5 has a sensitivity of 80.7% for predict-
ing disease progression is remarkably similar to the 81%
sensitivity that was reported by AbuRahma et al,34 albeit
our study focuses on the utility of carotid duplex measure-
ments for predicting disease progression rather than for
making an initial diagnosis of carotid artery stenosis. Also
similar to the ﬁndings by AbuRahma et al,34 we found no
additive beneﬁt to combining multiple duplex measure-
ments in our model.
The limitations of our study deserve discussion. The
study design was a retrospective review of data abstracted
from the electronic medical records, which carries a stan-
dard risk of missing or inaccurate data recording that
cannot be rectiﬁed. We attempted to limit any bias the
study design might carry by limiting our analysis to patients
with at least 1 year of follow-up. In addition, all clinical pre-
diction models were calculated from carotid duplex studies
performed by a fully accredited laboratory technician and
interpreted by board-certiﬁed vascular surgeons who had
no knowledge of the patients’ clinical details.
Another limitation to our study is that there is no
currently available database with which we can validate
our ICA/CCA prediction model; to date, our study is
the largest that we know of to report the natural history
of disease progression among patients with moderate
(50%-69%) ASCAS, so ﬁnding a second population to
test our ICA/CCA ratio cutoffs is not currently feasible.
We performed subgroup analyses and split-sample training
within the patients in our cohort in an attempt to show reli-
ability of the model and found no differences in predictive
efﬁcacy of the ICA/CCA ratio cutoffs that we identiﬁed,
regardless of patients’ clinical characteristics or previously
recognized risk factors for atherosclerotic disease. However,
future studies assessing the cost-effectiveness of our pro-
posed surveillance algorithm or similar approaches formoni-
toring patients with moderate ASCAS are needed to allow
for prospective validation of our model.CONCLUSIONS
Our data suggest that patients with ASCAS and an
ICA/CCA ratio >2.5 may warrant routine surveillance
for carotid artery disease progression beyond an initial ul-
trasound study. We propose an algorithm for the surveil-
lance of high-risk patients that we hope will allow for
maximal predictive ability in a cost-effective manner and
that could potentially be applied in a prospective fashion
to aid in the early diagnosis and intervention of patients
at high risk for progression of moderate to severe carotid
artery stenosis.
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